Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | PGK1 | P00558 | 1/20 | 0.46 |
| ▸ | PGK2 | P07205 | 1/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | PDE5A | O76074 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22070781 | 0.91 | AKR1B1 (0.41) | AKR1B1TDP1NPSR1PGK1PGK2 | |
| SCHEMBL27860588 | 0.89 | AKR1B1 (0.44) | AKR1B1TDP1NPSR1PGK1PGK2 | |
| SCHEMBL8538485 | 0.86 | HSD17B10 (0.44) | AKR1B1TDP1NPSR1GABRA5GABRB2 | |
| SCHEMBL29781424 | 0.85 | AKR1B1 (0.48) | AKR1B1TDP1GABRA5GABRB2HSD17B10 | |
| SCHEMBL2731062 | 0.85 | GABRA5 (0.47) | AKR1B1TDP1GABRA5GABRB2HSD17B10 | |
| SCHEMBL29684288 | 0.85 | KMT2A (0.53) | AKR1B1TDP1NPSR1KDM4ESMN1; SMN2 | |
| SCHEMBL869497 | 0.85 | KMT2A (0.53) | AKR1B1TDP1NPSR1KDM4ESMN1; SMN2 | |
| SCHEMBL12327392 | 0.85 | KDM4E (0.46) | AKR1B1TDP1GABRA5GABRB2HSD17B10 | |
| SCHEMBL868262 | 0.85 | AKR1B1 (0.48) | AKR1B1TDP1GABRA5GABRB2HSD17B10 | |
| SCHEMBL2730766 | 0.85 | FAAH (0.43) | AKR1B1TDP1GABRA5GABRB2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108530243-B | Process for the manufacture of nitriles and their corresponding amines | 中国石化扬子石油化工有限公司 | 2022-05-27 | — | — | CN | claimed |
| CN-108546224-B | Process for the manufacture of nitriles and their corresponding amines | 中国石化扬子石油化工有限公司 | 2022-05-27 | — | — | CN | claimed |
| CN-108530244-B | Process for the manufacture of nitriles and their corresponding amines | 中国石化扬子石油化工有限公司 | 2022-02-11 | — | — | CN | claimed |
| US-10953042-B2 | Vanadium insulin-mimetics, methods of preparation, and methods for treatment of diabetes | THE UNIVERSITY OF TRINIDAD AND TOBAGO (TT) | 2021-03-23 | — | — | US | claimed |
| US-20200138857-A1 | VANADIUM INSULIN-MIMETICS, METHODS OF PREPARATION, AND METHODS FOR TREATMENT OF DIABETES | THE UNIVERSITY OF TRINIDAD AND TOBAGO (TT) | 2020-05-07 | — | — | US | claimed |
| WO-2018222169-A2 | VANADIUM INSULIN-MIMETICS, METHODS OF PREPARATION, AND METHODS FOR TREATMENT OF DIABETES | THE UNIVERSITY OF TRINIDAD AND TOBAGO (TT) | 2018-12-06 | — | — | WO | claimed |
| US-7618913-B2 | Coordination catalyst containing an organosilicon compound , nitrogen compound, transition metal compound and magnesiumon compound on catalyst support | FORMOSA PLASTICS CORPORATION, U.S.A. (US) | 2009-11-17 | — | — | US | claimed |
| WO-2008027479-A2 | HIGHLY ACTIVE ALPHA-OLEFIN COPOLYMERIZATION CATALYST SYSTEM | FORMOSA PLASTICS CORPORATION, U.S.A. (US) | 2008-03-06 | — | — | WO | claimed |
| US-20080058198-A1 | Highly active alpha-olefin copolymerization catalyst system | FORMOSA PLASTICS CORPORATION, U.S.A. | 2008-03-06 | — | — | US | claimed |
| JP-9176520-A | — | — | None | — | — | JP | disclosed |
| US-11952445-B2 | Ethylene/alpha-olefin copolymers for better optical and mechanical properties and processability of film made therefrom | FORMOSA PLASTICS CORPORATION, USA (US) | 2024-04-09 | — | — | US | disclosed |
| CN-108530243-B | Process for the manufacture of nitriles and their corresponding amines | 中国石化扬子石油化工有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-108546224-B | Process for the manufacture of nitriles and their corresponding amines | 中国石化扬子石油化工有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20220153886-A1 | Ethylene/Alpha-Olefin Copolymers for Better Optical and Mechanical Properties and Processability of Film Made Therefrom | FORMOSA PLASTICS CORPORATION, USA | 2022-05-19 | — | — | US | disclosed |
| EP-0915088-B1 | D-Proline derivatives | HOFFMANN LA ROCHE (CH) | 2002-09-18 | — | — | EP | disclosed |
| US-6262089-B1 | USING THESE COMPOUNDS TO TREAT DISEASES ASSOCIATED WITH AMYLOIDOSIS, SUCH AS ALZHEIMER'S DISEASE, MATURITY ONSET DIABETES MELLITUS, FAMILIAL AMYLOID POLYNEUROPATHY, SCRAPIE, AND KREUZFELD-JACOB DISEASE. | HOFFMAN-LA ROCHE INC. | 2001-07-17 | — | — | US | disclosed |
| US-6103910-A | FOR TREATMENT OF DISEASES ASSOCIATED WITH AMYLOIDOSIS, SUCH AS ALZHEIMER'S DISEASE, DIABETES MELLITUS, FAMILIAL AMYLOID POLYNEUROPATHY, SCRAPIE, AND KREUZFELD-JACOB DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2000-08-15 | — | — | US | disclosed |
| CN-1217327-A | D-proline derivative | HOFFMANN LA ROCHE (CH) | 1999-05-26 | — | — | CN | disclosed |
| EP-0915088-A1 | D-Proline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-05-12 | — | — | EP | disclosed |
| JP-H09176520-A | PRIMER COMPOSITION AND MOLDED ARTICLE HAVING PRIMER LAYER | NIPPON ZEON CO LTD | 1997-07-08 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10953042-B2 | Vanadium insulin-mimetics, methods of preparation, and methods for treatment of diabetes | IAPP, INSR, GPR119 | AKR1B1 1034/4885TDP1 4080/4885NPSR1 3374/4885 |
| US-20200138857-A1 | VANADIUM INSULIN-MIMETICS, METHODS OF PREPARATION, AND METHODS FOR TREATMENT OF DIABETES | IAPP, INSR, GPR119 | AKR1B1 1034/4885TDP1 4080/4885NPSR1 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.